ArticleInternational journal of clinical and experimental pathology2020
Resolvin D2 prevents inflammation and oxidative stress in the retina of streptozocin-induced diabetic mice.
Article in International journal of clinical and experimental pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Role play of regulatory T cells and resolvins in type 2 diabetes.Frontiers in immunology · 2026Review
- Resolvin D2 Reduces UVB Skin Pathology by Targeting Cytokines, Oxidative Stress, and NF-κB Activation.Antioxidants (Basel, Switzerland) · 2025Article
- miR-130a-3p enhances autophagy through the YY1/PI3K/AKT/mTOR signaling pathway to regulate macrophage polarization and alleviate diabetic retinopathy.Journal of diabetes investigation · 2025Article
- RvD2 mitigates TNFɑ-Induced mitochondrial reactive oxygen species through NRF2 signaling in placental trophoblasts.Frontiers in physiology · 2025Article
- New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is the main ocular complication of diabetes mellitus. The aim of this study was to investigate the protective effect and mechanism of resolvin D2 (RvD2) on diabetic retinopathy. Streptozocin-induced C57/BJ diabetic mice were divided into three groups: normal control, diabetes mellitus, and diabetes plus RvD2 treatment. After three months of diabetic model induction, exogenous RvD2 was injected, monthly for three months, into the vitreous cavity of mice in the diabetic treatment group. Retinal vascular leakage, ganglion cell apoptosis, inflammatory factor expression, and oxidative stress factors were detected one month after the last injection. The levels of retinal vascular leakage and ganglion cell apoptosis in diabetic mice treated with RvD2 were significantly lower than those in untreated diabetic mice, as were the retinal levels of inflammatory factors and oxidative stress. In conclusion, RvD2 might be used as a retinal protective factor for diabetes mellitus by reducing inflammation and oxidative stress.
Indexed as
Identifiers
32922593PMC7476937W3085250489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.